Table 1.
Normoxic C10 Hemodyanmic Data.
| Baseline | Dobutamine | Esmolol | Significance | |
|---|---|---|---|---|
| Heart Rate (bpm) | 380 ± 0.52 (2) | 536 ± 2.41 (2) | 384 ± 2.63 (2) | c |
| End-Systolic Pressure (mmHg) | 79.3 ± 5.21 (2) | 100 ± 0.11 (2) | 62 ± 14.4 (2) | c,e |
| End-Diastolic Pressure (mmHg) | 12.4 ± 4.7 (2) | 13.2 ± 7.15 (2) | 11.5 ± 2.06 (2) | |
| Maximum dP/dt (mmHg/s) | 4804 ± 529 (2) | 12839 ± 1339 (2) | 3373 ± 1157 (2) | a,e |
| Minimum dP/dt (mmHg/s) | 4434 ± 1120 (2) | 10208 ± 628 (2) | 3130 ± 1572 (2) | c,d,e |
| Tau (msec) | 11.5 ± 2.21 (2) | 6.46 ± 1.73 (2) | 16.5 ± 5.48 (2) | |
| End-Diastolic Volume (μl) | 59.6 ± 5.53 (2) | 62 ± 14.9 (2) | 66.2 ± 6.21 (2) | |
| End-Systolic Volume (μl) | 43.8 ± 3.63 (2) | 29.9 ± 13.3 (2) | 53.8 ± 9.23 (2) | |
| Cardiac Output (μl/min) | 8129 ± 635 (2) | 20915 ± 143 (2) | 7341 ± 1644 (2) | |
| PRSW (mmHg⋅μl/μl) | 72.4 ± 14.8 (2) | 89.6 ± 36.2 (2) | 24.1 ± 20.4 (2) |
Significant testing by three-way ANOVA with genotype, oxygen therapy protocol, and hemodynamic protocol treatment as factors with Tukey post-hoc test. a; signifies difference between baseline and dobutamine with normoxic protocol in C10 mice; b: signifies difference between baseline and esmolol with normoxic treatment in C10 mice; c: signifies an overall genotype effect; d: represents an overall difference between normoxia and HBOT treatment; e: represents an overall difference between normoxia and hyperoxic treatment.